Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
Imprimis Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 25, 2019
Imprimis Pharmaceuticals reported fiscal year 2018 executive compensation information on April 25, 2019.
In 2018, three executives at Imprimis Pharmaceuticals received on average a compensation package of $729K, a 17% increase compared to previous year.
Average pay of disclosed executives at Imprimis Pharmaceuticals
Mark L. Baum, Chief Executive Officer, received $1.1M in total, which increased by 16% compared to 2017. 40% of Baum's compensation, or $425K, was in non-equity incentive plan. Baum also received $204K in option awards, $411K in salary, $4.4K in stock awards, as well as $13K in other compensation.
John P. Saharek, Chief Commercial Officer, received a compensation package of $580K, which increased by 34% compared to previous year. 47% of the compensation package, or $275K, was in salary.
Andrew R. Boll, Chief Financial Officer, earned $551K in 2018, a 5% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 25, 2019.